Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5243-5254

  Buckheit, Karen Watson ^a   Yang, Lu ^a   Buckheit Jr , Robert W ^a  

^a ImQuest Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; IQP 0405; IQP 0406; IQP 0407; IQP 0410; IQP 0528; IQP 0529; IQP 0531; IQP 0549; IQP 0554; IQP 0558; IQP 0565; IQP 1187; MICROBICIDE; PYRIMIDINEDIONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LACTOBACILLUS; MACROPHAGE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; VAGINA FLORA; VIRUS ENTRY; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; HIV; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; PYRIMIDINONES;

EID: 80054708457     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05237-11     Document Type: Article

References (40)

1. Abdool Karim, Q., et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
2. Baba, M., et al. 1988. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 85:6132-6136.
3. Blocker, M. E., and M. S. Cohen, 2000. Biologic approaches to the prevention of sexual transmission of human immunodeficiency virus. Infect. Dis. Clin. North Am. 14:983-999. (Pubitemid 32106674)
4. Buckheit, R. W., Jr., et al. 2008. Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2. Antimicrob. Agents Chemother. 52:225-236.
5. Buckheit, R. W., Jr., et al. 2007. The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors. Antivir. Chem. Chemother. 18:259-275.
6. Buckheit, R. W., Jr., et al. 1995. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39:2718-2727.
7. Buckheit, R. W., Jr., et al. 1997. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitorresistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 41:831-837.
8. Buckheit, R. W., Jr., and R. Swanstrom. 1991. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retrovir. 7:295-302.
9. Buckheit, R. W., Jr., et al. 2001. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother. 45:393-400. (Pubitemid 32106715)
10. Buckheit, R. W., Jr., et al. 2010. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res. 85:142-158.
11. Cairns, G. 2010. Six existing drug classes now being tested as microbicides. www.aidsmap.com/page/1438869.
12. Center for the AIDS Programme of Research in South Africa. 2010. Tenofovir gel reduces risk of HIV and genital herpes infection in women. CAPRISA, Congella, South Africa.
13. Clanton, D. J., et al. 1992. Sulfonic acid dyes: inhibition of the human immunodeficiency virus and mechanism of action. J. Acquir. Immune Defic. Syndr. 5:771-781.
14. Cloyd, M. W., and B. E. Moore. 1990. Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates. Virology 174:103-116. (Pubitemid 20030956)
15. CONRAD. 2009. CONRAD statement on MDP 301 results. http://www .conrad.org/news-pressreleases-42.html.
16. Damian, F., et al. 2010. Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions. Int. J. Pharm. 396:1-10.
17. D'Cruz, O. J., and F. M. Uckun. 2006. Dawn of non-nucleoside inhibitorbased anti-HIV microbicides. J. Antimicrob. Chemother. 57:411-423. (Pubitemid 43240192)
18. Dorr, P., et al. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732. (Pubitemid 41552605)
19. Fletcher, P., et al. 2009. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 53:487-495.
20. Grant, R. M., et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
21. .Grant, R. M., et al. 2008. Whither or wither microbicides? Science 321:532-534.
22. Halliday, S. M., et al. 1996. Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene. Antiviral Res. 33:41-53. (Pubitemid 26398137)
23. Kimpton, J., and M. Emerman, 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
24. Lackman-Smith, C., et al. 2008. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob. Agents Chemother. 52: 1768-1781. (Pubitemid 351614671)
25. .McCormack, S., et al. 2010. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376:1329-1337.
26. Mocroft, A., et al. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352:1725-1730. (Pubitemid 28534954)
27. Moore, J. 2006. Entry inhibitors as topical microbicides to prevent HIV-1 sexual transmission. Retrovirology 3(Suppl. 1):S51.
28. Morner, A., et al. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73:2343-2349. (Pubitemid 29098139)
29. Morris, G. C., and C. J. Lacey. 2010. Microbicides and HIV prevention: lessons from the past, looking to the future. Curr. Opin. Infect. Dis. 23:57-63.
30. Mulato, A. S., and J. M. Cherrington, 1997. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Res. 36:91-97. (Pubitemid 27522489)
31. Nakashima, H., et al. 1986. Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3′-azido-3′-deoxythymidine in vitro. Antimicrob. Agents Chemother. 30: 933-937. (Pubitemid 17209152)
32. Nara, P. L., et al. 1987. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res. Hum. Retrovir. 3:283-302. (Pubitemid 18040413)
33. Palella, F. J., Jr., et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
34. Phillips, D. M., et al. 1995. An assay for HIV infection of cultured human cervix-derived cells. J. Virol. Methods 52:1-13.
35. Popovic, M., et al. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500. (Pubitemid 14134740)
36. Romano, J., et al. 2008. Microbicide delivery: formulation technologies and strategies. Curr. Opin. HIV AIDS 3:558-566.
37. Turpin, J. A. 2002. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Invest. Drugs 11: 1077-1097.
38. UNAIDS. 2008. Report on the global AIDS epidemic: December 2008. UNAIDS, Geneva, Switzerland.
39. Watson, K. M., C. E. Buckheit, and R. W. Buckheit, Jr. 2008. Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay. Antimicrob. Agents Chemother. 52:2787-2796.
40. Watts, C., and C. Zimmerman. 2002. Violence against women: global scope and magnitude. Lancet 359:1232-1237. (Pubitemid 34304267)